NASDAQ$SMTI
Sanara MedTech Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Announced fourth quarter and full year 2021 results.
Sanara MedTech reported record sales results in both the fourth quarter and the full year, building on the success of their Cellerate product line and executing their strategy to offer a comprehensive solution for wound and skin care in all care settings.
- Built on the success of the Cellerate product line.
- Executed strategy to offer a comprehensive solution for wound and skin in all care settings.
- Achieved record sales results in both the fourth quarter and the full year.
- Focused on providing patients with efficacious solutions that improve outcomes at a lower overall cost.
Headline financials
Revenue & EPS history
Sanara MedTech · Revenue · Quarterly
$7.03M
Revenue by segment
Sanara MedTech · $31.6M total across 2 segments · Q2 2023
- Soft tissue repair$15.8M—50.0%
- Bone fusion products$15.8M—50.0%
Forward guidance
No specific forward guidance was provided in the press release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+0.2%
Avg return
Earnings day
-2.3%
Avg return
5 days after
+1.0%
Avg return
30 days after
34%
22 / 64 earnings
Positive
+28.6%
Q4 2014
Best reaction
-25.0%
Q3 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +13.0% | +17.3% | — | |
| Q4 2025 | -0.3% | -7.5% | +4.3% | |
| Q3 2025 | -23.4% | -24.9% | -7.6% | |
| Q1 2025 | -9.0% | -11.2% | -17.9% | |
| Q4 2024 | -12.6% | -15.4% | -10.4% | |
| Q3 2024 | +6.3% | -1.0% | +2.5% | |
| Q2 2024 | +14.9% | +16.3% | +20.2% | |
| Q1 2024 | -5.0% | -2.9% | -0.5% | |
| Q4 2023 | -1.8% | -1.1% | -13.1% | |
| Q3 2023 | +18.8% | +15.3% | +37.5% | |
| Q2 2023 | -12.5% | -13.6% | -22.6% | |
| Q1 2023 | -5.0% | -9.2% | -5.9% | |
| Q4 2022 | -0.1% | -4.1% | +17.9% | |
| Q3 2022 | +4.1% | +7.2% | +3.2% | |
| Q2 2022 | +1.2% | -1.7% | +13.4% | |
| Q1 2022 | +5.0% | +2.3% | -12.2% | |
| Q4 2021 | +2.5% | +10.7% | -10.9% | |
| Q3 2021 | -1.6% | -2.2% | -15.8% | |
| Q2 2021 | -8.3% | -12.4% | -14.5% | |
| Q1 2021 | +5.2% | +14.9% | +28.7% | |
| Q4 2020 | +14.5% | +6.8% | -4.5% | |
| Q3 2020 | -4.5% | -4.3% | +15.7% | |
| Q2 2020 | +9.8% | +13.7% | +37.2% | |
| Q1 2020 | -20.7% | -18.2% | +28.8% | |
| Q4 2019 | -4.3% | +7.3% | +30.9% | |
| Q3 2019 | -3.9% | -5.7% | +5.1% | |
| Q2 2019 | -11.5% | -20.1% | -17.2% | |
| Q1 2019 | +0.0% | -16.7% | -16.7% | |
| Q4 2018 | +0.0% | -16.7% | -16.7% | |
| Q3 2018 | +0.0% | +0.0% | +0.0% | |
| Q2 2018 | -10.0% | -10.0% | -30.0% | |
| Q1 2018 | +20.0% | +0.0% | +20.0% | |
| Q4 2017 | +20.0% | +0.0% | +20.0% | |
| Q3 2017 | +0.0% | +0.0% | -14.3% | |
| Q2 2017 | +0.0% | +16.7% | +16.7% | |
| Q1 2017 | +0.0% | +0.0% | -22.2% | |
| Q4 2016 | +0.0% | +0.0% | -10.0% | |
| Q3 2016 | -20.0% | -20.0% | +0.0% | |
| Q2 2016 | +20.0% | +0.0% | +0.0% | |
| Q1 2016 | +0.0% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +11.1% | — | — | |
| Q4 2014 | +28.6% | — | — | |
| Q3 2014 | +0.0% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +0.0% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +14.3% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +16.7% | — | — | |
| Q4 2012 | -12.5% | — | — | |
| Q3 2012 | -16.7% | — | — | |
| Q2 2012 | +6.7% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | -4.3% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | -10.3% | — | — | |
| Q1 2011 | -11.1% | — | — | |
| Q4 2010 | +3.1% | — | — | |
| Q3 2010 | -25.0% | — | — | |
| Q2 2010 | +2.9% | — | — | |
| Q1 2010 | +5.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro